Background : Incidence and risk factors for delirium during clozapine treatment require further
clarification. Methods : We used computerized pharmacy records to identify all adult psychiatric inpatients
treated with clozapine (1995-96), reviewed their medical records to score incidence
and severity of delirium, and tested associations with potential risk factors. Results : Subjects (n = 139) were 72 women and 67 men, aged 40.8 ± 12.1 years, hospitalized
for 24.9 ± 23.3 days, and given clozapine, gradually increased to an average daily
dose of 282 ± 203 mg (3.45 ± 2.45 mg/kg) for 18.9 ± 16.4 days. Delirium was diagnosed
in 14 (10.1 % incidence, or 1.48 cases/person-years of exposure); 71.4 % of cases
were moderate or severe. Associated factors were co-treatment with other centrally
antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization
(by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily
clozapine dose, which fell with age, were unrelated. Conclusions : Delirium was found in 10 % of clozapine-treated inpatients, particularly in older
patients exposed to other central anticholinergics. Delirium was inconsistently recognized
clinically in milder cases and was associated with increased length-of-stay and higher
costs, and inferior clinical outcome.
Key words
Anticholinergic - Clozapine - Delirium
References
centorf@mcleanpo.mclean.org
